Document Detail


Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study.
MedLine Citation:
PMID:  17195903     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: There is a growing interest for the use of local ablative techniques in patients with non-resectable colorectal liver metastases. Evidence on the efficacy over systemic chemotherapy is, however, extremely weak. In this prospective study we aim to assess the additional benefits of local tumour ablation. METHODS: A consecutive series of 201 colorectal cancer patients, without extrahepatic disease, that underwent laparotomy for surgical treatment of liver metastases, were prospectively followed for survival and HRQoL. At laparotomy three groups were identified: patients in whom radical resection of metastases proved feasible, patients in whom resection was not feasible and received local ablative therapy, and patients in whom resection or local ablation was not feasible for technical reasons and who received systemic chemotherapy. FINDINGS: Patients in the chemotherapy and in local ablation group were comparable for all prognostic variables tested. For the local ablation group overall survival at 2 and 5 years was 56 and 27%, respectively (median 31 months, n = 45), for the chemotherapy group 51 and 15%, respectively (median 26 months, n = 39) (P = 0.252). After resection these figures were 83 and 51%, respectively (median 61 months, n = 117) (P < 0.001). The median DFS after local ablation was 9 months, HRQoL was restored within 3 months. Patients after local ablation gained far more QALY's (317) than in the chemotherapy group (165) (P < 0.001). INTERPRETATION: Although overall survival did not reached statistical significance, the median DFS of 9 months suggests a beneficial effect of local tumour ablation for non-resectable colorectal liver metastases. Moreover, compared with systemic chemotherapy more QALY's were gained after local ablative therapy.
Authors:
Theo J M Ruers; Joris J Joosten; Bastiaan Wiering; Barbara S Langenhoff; Heleen M Dekker; Theo Wobbes; Wim J G Oyen; Paul F M Krabbe; Cornelis J A Punt
Related Documents :
19546553 - Local ablative therapies in hcc: percutaneous ethanol injection and radiofrequency abla...
19075173 - Colorectal liver metastases: recurrence and survival following hepatic resection, radio...
15816603 - Paclitaxel plus gemcitabine in advanced non-small cell lung cancer patients with low pe...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2006-12-31
Journal Detail:
Title:  Annals of surgical oncology     Volume:  14     ISSN:  1068-9265     ISO Abbreviation:  Ann. Surg. Oncol.     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-03-09     Completed Date:  2007-06-12     Revised Date:  2007-07-18    
Medline Journal Info:
Nlm Unique ID:  9420840     Medline TA:  Ann Surg Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1161-9     Citation Subset:  IM    
Affiliation:
Department of Surgery, Division of Surgical Oncology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. T.Ruers@chir.umcn.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Catheter Ablation*
Colorectal Neoplasms / pathology,  therapy*
Combined Modality Therapy / methods
Cryotherapy
Female
Follow-Up Studies
Humans
Laparotomy
Liver Neoplasms / secondary*,  therapy*
Male
Middle Aged
Neoplasm Recurrence, Local / therapy
Neoplasm Staging / methods
Patient Selection
Preoperative Care / methods
Prospective Studies
Quality of Life
Survival Rate
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Serotonin and its role in colonic function and in gastrointestinal disorders.
Next Document:  Clinical characteristics and surgical outcome in hepatocellular carcinoma without hepatitis B virus ...